Upon successful completion of these requirements,
you will receive a printable credit statement.
If you have any
questions about this process, please email
the Center for Continuing and Outreach
Education at firstname.lastname@example.org or call CCOE Enrollment Services at (800) 227-4852.
Provided by the François-Xavier Bagnoud (FXB) Center, School of Nursing, Rutgers, The State University of New Jersey and the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences.
This activity is supported by an educational grant from the New Jersey Department of Health (NJDOH)—Division of HIV, STD and TB Services, through an MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS”.
Statement of Need
There is a complex interaction between HIV infection, inflammation, and the immune system. Antiretroviral therapy (ART) has evolved to a point where most persons living with HIV (PLWH) can achieve an undetectable viral load within 12 weeks of starting treatment. However, chronic inflammatory processes still occur even in well-controlled HIV infection. Therefore, in an effort to further improve disease outcome, methods to decrease chronic inflammation have become a new focus of research.
This activity will review the most common comorbidities encountered in PLWH and discuss their relationship to environmental and genetic risk factors, HIV-related inflammatory state, and ART.
This activity is designed for physicians, physician assistants, advanced practice nurses, nurses, and other health care professionals in New Jersey who are involved in the care of people infected with HIV.
Method of Participation
Participants should read the learning objectives, review the activity in its entirety, and then complete the self-assessment test, which consists of a series of multiple-choice questions. Upon completing this activity as designed and achieving a passing score of 70% or more on the self-assessment test and submitting a course evaluation, participants will receive a printable credit statement.
Upon completion of this activity, participants should be able to:
- Identify manifestations of inflammation in PLWH.
- Articulate benefits of early and continuous undetectable HIV viral load to decrease chronic inflammation.
- Recognize risk factors for common comorbidities in PLWH.
- Identify approaches to prevent and manage comorbidities and co-infection in order to control chronic inflammation.
Activity Director/Academic Advisor
Jihad Slim, MD
NJDOH-Division of HIV, STD and TB Services
Connie Calisti-Myers, JD,
NJDOH-Division of HIV, STD and TB Services
John Nelson, PhD, CPNP,
AETC NCRC, FXB Center, Rutgers University
Andrea Norberg, MS, RN,
FXB Center, Rutgers University
Shobha Swaminathan, MD,
Assistant Professor, Division of Infectious Diseases, Department of Medicine,
Rutgers New Jersey Medical School
Program Manager, FXB Center, Rutgers University
Macsu Hill, MPH, CHES,
Specialist, FXB Center, Rutgers University
Elizabeth Ward, MSJ,
Director, Rutgers CCOE
Jihad Slim, MD
Medical Director NJDOH Division
of HIV, STD and TB Services
Christopher F. Saling, MD
Saint Michael’s Medical Center
Rutgers, The State University of New Jersey is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Rutgers, The State University of New Jersey designates this enduring material for a maximum of .75 AMA PRA Category Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Rutgers, The State University of New Jersey, Center for Continuing and Outreach Education is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider Number P173-05/31/2016.
This activity is awarded .98 contact hours (60 minute CH).
Rutgers Center for Continuing and Outreach Education certifies that this continuing education offering meets the criteria for up to .1 Continuing Education Units (CEUs), provided the activity is completed as designed. One CEU equals 10 contact hours of participation in an organized continuing education experience under responsible sponsorship, capable direction and qualified instruction.
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by John Nelson, PhD, CPNP.
This activity was field tested for time required for participation by Noa’a Shimoni, MD, MPH, Marshall Glesby, MD, MPH, Lisa A. Pittarelli, MD, FACP, Anna M. Haywood, MSN, RN, Laura Bogert, BSN, RN, and Renée Powell, BS, RN.
In accordance with the disclosure policies of Rutgers University and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.
Jihad Slim, MD, receives grant/research support from Gilead Sciences and ViiV Healthcare. He is also a member of the Speakers Bureau for AbbVie, Bristol-Myers Squibb, Janssen Pharmaceuticals, Gilead Sciences, and Merck & Co.
Shobha Swaminathan, MD, is a member of the Advisory Board of and receives grant/research support from Gilead Sciences for HIV testing (grant provided to Rutgers University).
All other authors, planning committee members, peer reviewers and field testers have no relevant financial relationships to disclose.
Off-Label/Investigational Usage Disclosure
This activity contains information of commercial products/devices that are unlabeled for use or investigational
uses of products not yet approved. It describes the investigational use of non-approved products including rosuvastatin IL-7 and Saccharomyces boulardi for anti-inflammatory therapy in PLWH.
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDOH – Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or Rutgers University. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.
Copyright © 2016 Rutgers University
All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers University.
Please direct CE related or technical questions to Rutgers at 973-972-4267 or email email@example.com.